The sale of Cordis could fetch between $1.5 billion and $2 billion, one of the people told the Journal, adding that the sales process for the business was still at an early stage.
When contacted, J&J declined to comment on the matter.
Bridgewater, New Jersey based Cordis manufactures treatments for vascular disease including stents and catheters. It has a workforce of about 5000 employees.
Earlier this year, J&J sold another of its units, Ortho-Clinical Diagnostics Inc to private-equity firm for $4.15 billion.
Analysts had pointed out at that time that the move highlighted J&J’s determination not to waste resources on unloved divisions.
Other eminent deal talks in the medical device sector in recent times include Medtronic Inc’s $43 billion bid for Covidien Plc while Zimmer Holding Inc agreed to acquire Biomet Inc for about $13 billion. (Reuters)
